(Daclizumab)Biosimilar Reference Antibody-GS40160

货号：GS40160

Daclizumab (marketed under the brand name Zinbryta®) was a humanized monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). It functioned as an interleukin-2 (IL-2) receptor modulator, specifically designed to target a key pathway involved in aberrant T-cell activation, which is central to the autoimmune attack on the central nervous system in MS. It was administered via monthly subcutaneous injection. However, due to serious safety concerns—including severe liver injury, immune-mediated disorders, and reports of encephalitis—the drug was voluntarily withdrawn worldwide from the market in 2018.